This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Eugene B. Buynak, PhD; Robert R. Roehm; Alfred A. Tytell, PhD; Alexander U. Bertland II, PhD; George P. Lampson, MS; Maurice R. Hilleman, PhD, DSc

JAMA. 1996;276(22):1793-1795.

Abstract
• A highly purified and inactivated vaccine was made of hepatitis B virus surface antigen. The vaccine was tested exhaustively for safety by ordinary procedures and additionally in chimpanzees and marmosets. It was highly potent and induced antibody in guinea pigs, grivet monkeys, and chimpanzees after three doses of vaccine were given subcutaneously. Chimpanzees given three doses of vaccine were protected against challenge with 1,000 chimpanzee-infectious doses of live human hepatitis B virus given intravenously in controlled studies. Tests of the vaccine for control of hepatitis B in man are to be carried out.

Author Affiliations
From the Division of Virus and Cell Biology Research, Merck Institute for Therapeutic Research, West Point, Pa.

Footnotes
Reprint requests to Virus and Cell Biology Research, Merck Institute for Therapeutic Research, West Point, PA 19456 (Dr Hilleman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?